US recall of one lot of thyroid tablets

What was announced

Vitruvias Therapeutics announced on 21 August 2026 a nationwide recall in the US of one lot of Thyroid Tablets, USP 30 mg, and the US Food and Drug Administration (FDA) published the notice on 24 August 2026.

The recalled lot is number 504950, and the recall is to consumer level.

The reason given is that testing confirmed the product could be superpotent.

The notice says the company has received no reports of adverse events linked to the recall.

What it means

The notice says superpotent thyroid tablets can cause symptoms of an overactive thyroid, such as weight loss and changes in heart rate.

It describes older adults, pregnant women and infants as more vulnerable, especially with long-term use.

The notice says people currently using this lot should not stop without first talking to their healthcare provider, who can advise on next steps or a replacement prescription.

The FDA has said that animal-derived (desiccated) thyroid medicines are unapproved, meaning the agency has not reviewed them for safety, effectiveness or quality.

This is a US recall notice; any UK action on medicines is decided separately by the MHRA.